Stockreport

OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates

OS Therapies Incorporated  (OSTX) 
PDF First therapeutic candidate targets Breast Cancer, Lung Cancer and Gastric CancerSecond therapeutic candidate targets platinum-resistant Ovarian Cancer, Fallopian Tube C [Read more]